Dataset Information


MiR-195 Has a Potential to Treat Ischemic and Hemorrhagic Stroke through Neurovascular Protection and Neurogenesis.

ABSTRACT: Tissue plasminogen activator is the only U.S. FDA-approved therapy for ischemic stroke, while there is no specific medication for hemorrhagic stroke. Therefore, the treatment of acute stroke continues to be a major unmet clinical need. We explored the effects of miR-195 on neurovascular protection and its potential in treating acute stroke. Using both cellular and animal studies, we showed that miR-195's beneficial effects are mediated by four mechanisms: (1) anti-apoptosis for injured neural cells by directly suppressing Sema3A/Cdc42/JNK signaling, (2) neural regeneration by promoting neural stem cell proliferation and migration, (3) anti-inflammation by directly blocking the NF-kB pathway, and (4) improvement of endothelial functions. We intravenously injected miR-195 carried by nanoparticles into rats with either ischemic or hemorrhagic stroke in the acute stage. The results showed that miR-195 reduced the size of brain damage and improved functional recovery in both types of stroke rats. The reduction of injured brain volume could be up to 45% in ischemic stroke and approximately 30% in hemorrhagic stroke. The therapeutic window between stroke onset and miR-195 treatment could be up to 6 h. Our data demonstrated that miR-195 possesses the potential to become a new drug to treat acute ischemic and hemorrhagic stroke.


PROVIDER: S-EPMC6365409 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC4971736 | BioStudies
2020-01-01 | S-EPMC7439693 | BioStudies
2022-03-30 | GSE199435 | GEO
2019-01-01 | S-EPMC6413259 | BioStudies
2013-01-01 | S-EPMC3702293 | BioStudies
2020-01-01 | S-EPMC7385414 | BioStudies
2013-01-01 | S-EPMC3547917 | BioStudies
2018-01-01 | S-EPMC5807361 | BioStudies
1000-01-01 | S-EPMC3734770 | BioStudies
2018-01-01 | S-EPMC6095808 | BioStudies